Thanks to the scale-up of its drug discovery engine, ENYO Pharma has discovered a novel chemical series that potently targets the F protein of Respiratory syncytial virus (RSV-F) mediated fusion and cell entry. Inhibitors bind to a three-fold-symmetric pocket within the central cavity of RSV F glycoprotein to inhibit membrane fusion and have picomolar potency in in vitro fusion and viral production assays. The molecules are active on RSV A & B sub-types.

ENYO Pharma is seeking a collaboration to assess molecules in critical assays and initiate a shared risk partnership to progress to clinical development.